Ascentage Pharma Announces Promising Phase 1 Interim Results in Two Clinical Programs to Be Presented at 2018 ASCO Annual Meeting

Monday, May 21, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

ROCKVILLE, Md. and HONG KONG, May 21, 2018 /PRNewswire/ -- Ascentage Pharma, a global

clinical-stage biopharmaceutical company dedicated to developing apoptosis-targeted therapies for cancers and other diseases, today announced that interim results from two clinical programs will be presented at the 2018 American Society of Clinical Oncology
(ASCO) annual meeting in Chicago, June 1-5, 2018.

The poster sessions of APG-1252, a novel dual inhibitor of Bcl-2/Bcl-xL, and APG-1387, a IAP inhibitor, will be held on June 4.

"We are excited to present initial clinical experience with two of our pipeline candidates," commented Dr. Dajun Yang, Chairman and CEO of Ascentage. "These unique small molecules address complex, protein-protein interactions involved in apoptotic pathways in cancer. We look forward to continuing these single agent studies as well as combination trials with immunotherapy treatments."

ASCO abstracts include:

  • Title: A Phase 1 Study of Novel dual Bcl-2/Bcl-xL Inhibitor APG-1252 in Patients with Advanced Small Cell Lung Cancer (SCLC) or Other Solid TumorSession Date and Time: Monday, June 4 at 8:00 a.m.11:30 a.m. CDTAbstract Number: 2594APG-1252 was designed to reduce the target platelet toxicity seen with dual inhibitors Bcl-2/Bcl-xL, while maintaining strong antitumor activity. Preliminary results showed that APG-1252 was well-tolerated with no hematologic toxicity reported. There was one confirmed partial response in a metastatic small cell lung cancer (SCLC) patient. Dose escalation continues in SCLC and other solid tumors.
  • Title: A Phase 1 Study of a Novel IAP Inhibitor APG-1387 In Patients With Advanced Solid Tumors Session Date and Time: Monday, June 4 at 8:00 a.m.11:30 a.m. CDTAbstract Number: 2593APG-1387 was well-tolerated with manageable adverse events. Preliminary responses indicated positive host immune responses, suggesting synergy with immunotherapy agents. Studies are continuing with APG-1387 in combination with immunotherapy agents in patients with advanced solid tumors or hematologic malignancies.

About Ascentage Pharma

Ascentage Pharma is a globally-focused, clinical-stage biopharmaceutical company developing novel small molecule therapies for cancers, hepatitis B and age-related diseases. Based on breakthrough technology from the University of Michigan, the Company's expertise is in designing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death, in cancers. Ascentage has built a rich pipeline of seven clinical candidates, including a novel, highly potent Bcl-2/Bcl-xL inhibitor, APG-1252, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors. For more information, please visit

Media ContactAmy Bonanno E-mail: Phone: +1 914 450 0349

Investor ContactChad RubinE-mail: Phone: +1 646 378 2947

Cision View original content:

SOURCE Ascentage Pharma

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store